Koers Tilray, Inc. London S.E.
Aandelen
0UI4
CA03765K1049
Farmaceutische producten
Omzet 2024 * | 784 mln. 1,07 mld. 716 mln. | Omzet 2025 * | 866 mln. 1,18 mld. 791 mln. | Marktkapitalisatie | 1,59 mld. 2,18 mld. 1,46 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -217 mln. -297 mln. -198 mln. | Nettowinst (verlies) 2025 * | -69 mln. -94,39 mln. -63,07 mln. | EV/omzet 2024 * | 2,37 x |
Nettoschuld 2024 * | 264 mln. 361 mln. 241 mln. | Nettoschuld 2025 * | 319 mln. 436 mln. 292 mln. | EV/omzet 2025 * | 2,21 x |
K/w-verhouding 2024 * |
-5,98
x | K/w-verhouding 2025 * |
-19,8
x | Werknemers | 1.600 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,76% |
Recentste transcriptie over Tilray, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 30-04-21 |
Carl Merton
DFI | Director of Finance/CFO | - | 30-04-21 |
Lloyd Brathwaite
CTO | Chief Tech/Sci/R&D Officer | - | 30-04-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 30-04-21 |
David Clanachan
BRD | Director/Board Member | 62 | 30-04-21 |
Walter Robb
BRD | Director/Board Member | 70 | 30-04-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+55,35% | 848 mld. | |
+31,64% | 627 mld. | |
-0,10% | 363 mld. | |
+15,47% | 318 mld. | |
+13,10% | 299 mld. | |
+15,51% | 243 mld. | |
+16,72% | 225 mld. | |
+16,54% | 179 mld. | |
+4,31% | 167 mld. |